Merrimack Pharmaceuticals Inc MACK Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$15.13 unchanged at close May 28
Last close · Previous close $15.13
- Market cap
- $219.63MAt the May 28 close
- P/E ratio
- 1.09On last 12 months’ EPS
- Diluted EPS
- $13.87Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$15.13up $0.40, 2.72%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$15.13May 24
- Volume0.00May 28 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume358.06KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the May 28 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | MACK |
|---|---|
| Short term | |
| 1M | MACK: up 105.2% |
| 3M | MACK: up 105.6% |
| YTD | MACK: up 125.4% |
| 1Y | MACK: up 141.8% |
| Long term | |
| 3Y | MACK: up 372.3% +67.8% a year |
| 5Y | MACK: up 773.9% +54.3% a year |
| 10Y | MACK: down 1.5% −0.2% a year |
$10,000 invested in MACK 10 years ago (May 28, 2014) would be worth about $9,848 at the close on , with dividends reinvested.
| Period | MACK |
|---|---|
| Short term | |
| 1M | MACK: up 2.7% |
| 3M | MACK: up 2.9% |
| YTD | MACK: up 12.8% |
| 1Y | MACK: up 21.0% |
| Long term | |
| 3Y | MACK: up 136.4% +33.2% a year |
| 5Y | MACK: up 205.2% +25.0% a year |
| 10Y | MACK: down 76.2% −13.4% a year |
$10,000 invested in MACK 10 years ago (May 28, 2014) would be worth about $2,380 at the close on , not counting dividends.
All-time high
$107.55
Closing high on . Now 85.9% below that record.
Split-adjusted daily closes since Mar 29, 2012.
Stock splits
2
Latest: 1.27-for-1 on . Share counts adjust after each split.
Both splits
- 1.27-for-1
- 1-for-10
Valuation
The May 28 close compared with the last 12 months of reported results (the four quarters to Mar 31, 2024). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
1.1×The May 28 close ÷ diluted EPS over the last 12 months ($13.87)
Other valuation measures
- 1.0×Book value as of Mar 31, 2024
Price relative to accounting equity (book value) per share on the Mar 31, 2024 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −0.1×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - −1.13%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$24.48MAt the May 28 close
What it would cost to buy the whole business: the market cap at the May 28 close, plus debt, minus cash and short-term investments from the Mar 31, 2024 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own MACK DCF in Excel. Value Merrimack Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY24, the quarter ended Mar 31, 2024. “Last 12 months” means the four quarters from Apr 1, 2023 to Mar 31, 2024, and balance-sheet figures are as of Mar 31, 2024.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- $200.46M
- Diluted EPS
- $13.87
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY22 (Jun 30, 2022) | $0.00 | −$478.00K | −$0.04 |
| Q3 FY22 (Sep 30, 2022) | $0.00 | −$442.00K | −$0.03 |
| Q4 FY22 (Dec 31, 2022) | $0.00 | −$492.00K | −$0.03 |
| Q1 FY23 (Mar 31, 2023) | $0.00 | −$271.00K | −$0.02 |
| Q2 FY23 (Jun 30, 2023) | $0.00 | −$391.00K | −$0.03 |
| Q3 FY23 (Sep 30, 2023) | $0.00 | −$279.00K | −$0.02 |
| Q4 FY23 (Dec 31, 2023) | $0.00 | −$240.00K | −$0.01 |
| Q1 FY24 (Mar 31, 2024) | $0.00 | $201.37M | $13.93 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$3.03M | −$0.23 |
| FY21 (Dec 31, 2021) | $0.00 | −$2.46M | −$0.18 |
| FY22 (Dec 31, 2022) | $0.00 | −$1.54M | −$0.11 |
| FY23 (Dec 31, 2023) | $0.00 | −$1.18M | −$0.08 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$2.48MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$2.48MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $1.83MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $244.11MAs of Mar 31, 2024
Cash plus short- and long-term marketable securities on the Mar 31, 2024 balance sheet.
- Total debt$0.00As of Mar 31, 2024
- Net cash$244.11MAs of Mar 31, 2024
- 10.78As of Mar 31, 2024
Current assets divided by current liabilities on the Mar 31, 2024 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Mar 31, 2024
Total debt divided by shareholders’ equity on the Mar 31, 2024 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 288.2%Last 12 months
Over the last 12 months, Merrimack Pharmaceuticals’s net income was 288.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 265.3%Last 12 months
Over the last 12 months, Merrimack Pharmaceuticals’s net income was 265.3% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $8.30 |
| 2018 | $0.000 |
| 2019 | $2.00 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $15.10 |
| 2025 | $0.000 |
| 2026 (to date) | $0.000 |
Dividend details
- $0.00Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 0.00%; 5-yr low 3.83%, 5-yr high 99.80%Last 12 months
Dividends paid over the last 12 months as a share of the May 28 close. The bar shows where that yield sits in its range over the past five years; the median was 8.13%.
- $15.10Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
About Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administration (“FDA”) of ONIVYDE for certain additional clinical indications. ONIVYDE® is already approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack’s agreement with Ipsen does not require Ipsen to provide Merrimack with any information on the progress of ONIVYDE clinical trials that is not publicly available. Merrimack is also entitled to receive up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
MACK news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
MACK stock FAQ
What is MACK stock’s price today?
Merrimack Pharmaceuticals (MACK) traded at $15.13 at the close on , unchanged from the previous close of $15.13.
If you invested $1,000 in MACK 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in MACK on would be worth about $985 at the close on , a total return of −1.5%. The same $1,000 would be worth $8,739 if invested five years ago and $2,418 if invested one year ago. Past performance doesn’t predict future returns.
What is Merrimack Pharmaceuticals’s market cap?
Merrimack Pharmaceuticals’s market capitalization is about $219.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $15.13 (how market cap works). Merrimack Pharmaceuticals reported 14.52M shares outstanding at the end of its latest quarter ().
What is MACK’s P/E ratio?
MACK trades at 1.1 times its diluted earnings over the four quarters to ($13.87 per share), at the close. (How the P/E ratio works.)
What are MACK’s earnings per share?
MACK’s diluted earnings per share were $13.87 over the four quarters to , compared with −$0.12 in the twelve months before. The latest quarter (Q1 FY24) brought $13.93 per share, against −$0.02 a year earlier (how EPS works).
Does MACK pay a dividend?
Merrimack Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is MACK’s all-time high?
MACK’s highest closing price was $107.55 on , adjusted for stock splits. At $15.13 at the close on , it is 85.9% below that record.
Has MACK stock ever split?
Yes, twice: 1-for-10 on ; 1.27-for-1 on .
How has MACK stock performed?
Including dividends and measured to the close on , MACK has returned +125.4% so far this year and +141.8% over the past year, and +773.9% over five years (+54.3% a year). Past performance doesn’t predict future returns.
What sector and industry is Merrimack Pharmaceuticals in?
Merrimack Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does MACK trade on?
Merrimack Pharmaceuticals trades on the Nasdaq under the ticker symbol MACK. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.